United Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 74 to 96.
Discover The 3 Keys To Successful Stock Investing
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
United Therapeutics is not currently near a proper buy point. See if the stock goes on to form a new base and offer a new buying opportunity.
The stock sports an 84 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 84% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 10% increase in earnings for Q2. Sales growth fell to 12%, down from 17% in the prior quarter.
United Therapeutics earns the No. 9 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
